FESCIOF
10.3.2023 00:11:39 CET | Business Wire | Press release
The Future of Education, Science, and Culture International Organizations Forum (FESCIOF) successfully ended its inaugural convening in Riyadh, uniting for the first time the Arab League Educational, Cultural and Scientific Organization (ALECSO), the Islamic World Educational, Scientific and Cultural Organization (ICESCO), and the United Nations Educational, Scientific and Cultural Organization (UNESCO) plus more than 100 international organizations, leveraging the power of collaboration to drive meaningful impact for the future of international organizations in the fields of education, science, and culture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005847/en/
(from left to right) H.E. Mohamed Ould Amar, Director General, ALECSO, H.E. Dr. Salim Al Malik, ICESCO and Costanza Farina, Director, Regional Bureau for Education in the Arab States – UNESCO Representative to Lebanon and Syria (Photo: AETOSWire)
After the forum concluded, the organizers announced their commitment to facilitate further collaboration among international organizations in education, science, and culture. They affirmed the importance of FESCIOF as an innovative effort to align efforts and maximize positive impact through collaboration. Saudi Arabia also took the initiative to host the next two editions of FESCIOF, in 2025 and 2027.
FESCIOF, which featured more than 20 panel sessions with more than 65 speakers under the theme of “Together for Impact in the 21st Century,” aimed to foster insightful discourse and facilitate knowledge exchange to develop a shared vision and identify opportunities for collaboration.
Alongside high-level representatives from UNESCO, ALECSO, and ICESCO, the event facilitated cross-organizational dialogue within a broad ecosystem of change-makers, featuring speakers and attendees from international organizations, including the Islamic Development Bank (IsDB) Group and the United Nations Development Programme (UNDP), as well as experts and thought leaders in organizational design and management from prestigious academic institutions and prominent organizations, such as Harvard Business School, London Business School, INSEAD Blue Ocean Strategy Institute, Google, and Visa, among others.
The representatives from the education, culture and science international organizations reflected on the discussions during the Forum and highlighted its successes, recognizing the value that partnerships between civil society and the private sector bring to the world. During the final session “Preparing the Ground for Future Collaboration,” the panelists, H.E. Mohamed Ouled Amar, Director General of ALECSO; H.E. Dr. Salim Al-Malik, Director General of ICESCO; Costanza Farina, Director Regional Bureau in Beirut and Representative of UNESCO to Lebanon and Syria, emphasized the need to continue working together to create a “Together for Impact” roadmap to achieve shared goals and create a better future for all.
“As organizations and those who are organizing, we need to work at the right time and the right place because the challenge is the value of time,” H.E. Al-Malik said. He also praised the objectives of FESCIOF and said that ICESCO will maximize the conference outcomes and “convert them into action.”
Farina highlighted the interdependence of the three sectors of education, culture, and science, stressing, “we cannot advance on education if we do not advance in science and in culture at the same time.”
Finally, H.E. Mohamed Ould Amar, Director General of ALECSO concluded that “the goals from this Forum are crystal clear, we are working together to achieve them.”
FESCIOF aims to establish a collaborative and trusted global platform for international organizations to come together and capitalize on future opportunities. The event fosters open dialogue and partnership among stakeholders to create a roadmap for international organizations to collaborate more effectively, while establishing a sustainable mechanism for partnerships resulting from the forum.
FESCIOF, which took place from 8-9 March, is jointly organized by the ALECSO and the SNC.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005847/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom